This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NDRG3 / Protein NDRG3 · IHC design guide
Design Immunohistochemistry for NDRG3
Plan chromogenic NDRG3 IHC around cytoplasmic staining and strong signal in neuronal and intestinal glandular cells (HPA tissue IHC). The guide covers paraffin-section controls, fixation and interpretation, with a catalog antibody dilution of 0.5–1 μg/mL (datasheet A10017).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NDRG3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic; high in neuronal and intestinal glandular cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A10017) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent (standard IHC practice; not target-specific); target-specific effects are unknown. | |
| Caveat | Staining and RNA show medium consistency; verify specificity (HPA tissue IHC) | |
| Regulation | Brain-enhanced expression (UniProt; HPA RNA) | |
| Isoform / epitope | 3 isoforms; check epitope coverage across variants (UniProt) |
Section 1
Recommended NDRG3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published NDRG3 staining details for ovarian, thyroid and liver tissues (PMC12091667; PMC9811643; PMC6435526).
| Sample | Paraffin-embedded rat brain tissues; fixative not specified (datasheet A10017) |
| Fixation | Image fixative and duration unreported (datasheet A10017); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A10017) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A10017) |
| Primary antibody | Rabbit anti-NDRG3, 0.5-1μg/ml (datasheet A10017) |
| Primary incubation | Overnight at 4 °C (datasheet A10017) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10017) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NDRG3-positive staining in cells in granular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 for the catalog antibody (datasheet A10017). The cited excerpts do not report retrieval conditions (PMC12091667; PMC9811643; PMC6435526).
Section 2
What Is the Expected NDRG3 Staining Pattern?
NDRG3 should appear predominantly cytoplasmic in paraffin-section IHC, with strong staining in selected neurons, intestinal glandular cells, and late spermatids (HPA: cytoplasmic in most tissues; High in listed cells). UniProt describes a protein without a transmembrane segment but does not annotate its subcellular location (UniProt Q9UGV2 topology and subcellular record). Treat this as an expected pattern, not proof of antibody specificity: HPA rates tissue IHC Enhanced, with medium RNA–staining consistency and external verification pending (HPA: tissue IHC reliability).
| Clear cytoplasmic chromogen in cerebral-cortex neurons or cerebellar granular-layer cells, with visible cell boundaries (HPA: High in both cell populations). | This fits the reported IHC pattern when the signal belongs to the named cells and the tissue architecture is preserved (HPA: cytoplasmic expression in most tissues; High in brain cells). Compare staining across cells on the same section; a dark field alone does not establish the expected distribution (general IHC practice). |
| Predominantly nuclear or sharply membrane-restricted staining replaces cytoplasmic staining in an expected positive population. | Flag a compartment mismatch and check controls, detection, and antibody behavior before interpreting it as NDRG3 (HPA: cytoplasmic tissue pattern; cytosol in ICC-IF). UniProt provides no subcellular annotation, so this comparison identifies a discrepancy with HPA observations rather than proving that every noncytoplasmic signal is artefactual (UniProt Q9UGV2 subcellular record). |
| The strongest signal lies in adipocytes while nearby expected positive cells are weak or unstained (HPA: adipocytes Not detected). | Consider cross-reactivity or endogenous detection activity, especially if reagent controls show the same color (general IHC practice). HPA's adipocyte result offers a useful comparison, but its Enhanced rating and pending external verification do not make every other cell type a validated negative control (HPA: adipocytes Not detected; tissue IHC reliability). |
| Uniform chromogen covers several tissue compartments, obscures cell outlines, or also appears in the negative reagent control. | Treat this as background until a cell-resolved cytoplasmic pattern can be recovered (general IHC practice). Widespread NDRG3 tissue expression does not predict an even deposit across cells and extracellular spaces (UniProt Q9UGV2: ubiquitous tissue specificity; HPA: cytoplasmic expression in most tissues). |
| No convincing staining appears in cerebral-cortex neurons, cerebellar granular-layer cells, or colon glandular cells (HPA: High in each). | First suspect a failed staining run or insufficient assay sensitivity, then review section quality and controls (general IHC practice). One negative specimen cannot overturn the HPA reference pattern, and the HPA rating still warrants independent confirmation for a new assay (HPA: High in listed cells; Enhanced reliability, external verification pending). |
💡Expected NDRG3 appearanceCall a positive when a named HPA-high cell population shows distinct, predominantly cytoplasmic staining—such as cerebral-cortex neurons or colon glandular cells—while diffuse deposit, dominant nuclear signal, or strong adipocyte staining prompts review (HPA: tissue IHC pattern and cell-level scores; general IHC practice).
| Tissue and cell selection | Cortex neurons, cerebellar granular-layer cells, colon, duodenum and rectum glandular cells, and late spermatids are reported High; adipocytes are Not detected (HPA: tissue IHC). Compare the specified cell population, rather than treating an entire section as uniformly positive or negative (general IHC practice). |
| Strength of reference evidence | Both listed rabbit antibodies have Enhanced IHC status, while the tissue profile has medium consistency with RNA data and awaits external verification (HPA: antibody validation and tissue IHC reliability). Agreement with the pattern supports an interpretation but is not independent validation of a new antibody or staining run (general IHC practice). |
| Protein topology and processing | The annotated NDRG3 chain spans residues 1–375; no signal peptide, propeptide, or transmembrane segment is listed (UniProt Q9UGV2: processing and topology). These records give no basis to expect a membrane outline or shed extracellular staining. They do not, by themselves, establish an IHC compartment. |
| Isoforms and modified residues | UniProt lists three isoforms and modified residues including phosphorylation sites (UniProt Q9UGV2: isoforms and modified residues). Their effect on this IHC result cannot be assigned without antibody epitope information; do not attribute a staining difference to a particular isoform or phosphorylation state from these records alone. |
| IF/ICC Q&A: Where is NDRG3 seen? | HPA ICC-IF places NDRG3 mainly in the cytosol and additionally in vesicles, with images from A-431, HEL, and Hep-G2 (HPA: approved subcellular locations and ICC-IF images). That observation can guide compartment review, but it does not specify an IF/ICC protocol or make vesicular staining a required paraffin-IHC feature. |
| Detection background and retrieval decisions | If chromogenic detection uses HRP, endogenous peroxidase can contribute color; reagent controls help identify it (general IHC practice). Antigen retrieval may need empirical optimization for a new IHC assay (general IHC practice). Neither HPA nor UniProt supplies a target-specific fixation or retrieval sensitivity for NDRG3 (HPA: supplied tissue data; UniProt Q9UGV2). |
| Situation | Likely cause | Next action |
|---|---|---|
| High reference tissue is blank (HPA: High in cerebral-cortex neurons and colon glandular cells). | A run-level detection failure, unsuitable assay conditions, or low effective sensitivity is possible (general IHC practice). | Check the run's positive and reagent controls, section integrity, antibody application, and detection steps; optimize retrieval empirically if needed (general IHC practice). Do not infer NDRG3-specific fixation sensitivity from a blank slide (HPA: supplied tissue data; UniProt Q9UGV2). |
| Color is strongest over nuclei or cell borders in a proposed positive field. | The pattern conflicts with the predominantly cytoplasmic tissue reference and cytosolic ICC-IF location (HPA: tissue IHC and subcellular data). | Review morphology and counterstain, then compare reagent controls and the IHC-validated antibody's expected pattern (general IHC practice; HPA: Enhanced IHC antibodies). Record the mismatch before assigning biological meaning; UniProt has no independent location annotation (UniProt Q9UGV2). |
| Adipocytes stain strongly while expected positive cells do not (HPA: adipocytes Not detected; listed cells High). | Cross-reactivity or endogenous detection activity is plausible (general IHC practice). | Inspect reagent controls and compare the same run with a named HPA-high cell population (general IHC practice; HPA: tissue IHC). If HRP is used, assess endogenous peroxidase control performance (general IHC practice). |
| Diffuse color masks the cytoplasm throughout the section. | Nonspecific antibody binding, residual detection activity, or excessive chromogen development may obscure cell-resolved staining (general IHC practice). | Compare reagent controls; review blocking, antibody concentration, washing, and chromogen development using the assay's validated conditions (general IHC practice). Judge any recovered signal against HPA's predominantly cytoplasmic pattern (HPA: tissue IHC). |
| A low-staining tissue looks negative, but the run's positive control stains. | The selected cells may fall near the assay's detection threshold: HPA reports Low staining in salivary, pancreatic, placental, cardiac, smooth-muscle, and skeletal-muscle populations (HPA: tissue IHC). | Check that the intended cell population is present and score it separately from the positive control (general IHC practice). Avoid declaring antibody failure from a low-reference population alone (HPA: Low in listed cells). |
| A new antibody gives a convincing cytoplasmic pattern but different intensity from HPA images. | Assay conditions or antibody recognition may differ; HPA's tissue rating has medium RNA–staining consistency and awaits external verification (general IHC practice; HPA: tissue IHC reliability). | Compare named positive and negative-reference cells, controls, and compartment before scoring intensity (HPA: tissue IHC; general IHC practice). Without epitope information, do not assign the difference to one of the three isoforms or a modification (UniProt Q9UGV2: isoforms and modified residues). |
Experiment evidence
IHC & IF images showing NDRG3 staining
A10017 · IHCIHC analysis of NDRG3 using anti-NDRG3 antibody (A10017). NDRG3 was detected in paraffin-embedded section of rat brain tissues. Heat mediate
A10017 · IHCIHC analysis of NDRG3 using anti-NDRG3 antibody (A10017). NDRG3 was detected in paraffin-embedded section of human mammary cancer tissues. H
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000101079-NDRG3/tissue/cerebral+cortex#imid_4921420
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000101079-NDRG3/tissue/colon#imid_4921346
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000101079-NDRG3/tissue/liver#imid_4921347
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000101079-NDRG3/tissue/kidney#imid_4921332
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA018256; green = NDRG3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA018256; green = NDRG3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NDRG3 IHC & IF
🧪Run cerebellum first and expect staining in cells of the granular layer (HPA: High in cerebellar cells of the granular layer). Use adipose tissue as the negative tissue, with adipocytes expected to lack detectable staining (HPA: Not detected in adipocytes); on the cerebellum slide, assess background in areas outside the stained granular layer without assuming those cells are NDRG3-negative.
Positive control tissue: Cerebellum (Cells in granular layer, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NDRG3 in A-431, HEL, Hep-G2, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG isotype control matched to the primary antibody’s clonality (selected-SKU caption: rabbit anti-NDRG3 primary). Use NDRG3 knockout tissue as a biological specificity control when available; for chromogenic cerebellum IHC, quench endogenous peroxidase and check endogenous biotin background because the caption uses biotinylated secondary antibody and streptavidin–biotin detection (selected-SKU caption: SABC with DAB).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected-SKU paraffin-section caption does not state the fixative (selected-SKU caption: fixative not stated). The demonstrated IHC workflow uses heat retrieval in citrate buffer at pH 6 for 20 minutes, but whether retrieval is required has not been established (selected-SKU caption: heat-mediated citrate retrieval). No supplied comparison establishes that frozen sections or IF are easier; cerebellar background should be checked with the detection controls (selected-SKU caption: biotin-based DAB detection).
HPA tissue IHC evidence for NDRG3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Rectum | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NDRG3 IHC Tips
Troubleshoot NDRG3 staining in paraffin sections by checking retrieval, cellular pattern, controls, and scoring against the available tissue evidence.
What retrieval should I start with for NDRG3 in paraffin sections?
Start with heat-mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A10017). The documented rat brain IHC used 1 μg/ml catalog antibody overnight at 4°C after that retrieval (datasheet A10017). If staining is weak, compare retrieval heating and cooling conditions on adjacent sections while holding antibody concentration and detection constant (general IHC practice). Include a known staining reference, such as cerebral cortex neuronal cells, and a no-primary control so that increased signal can be assessed alongside background (HPA: High in cerebral cortex neuronal cells; general IHC practice).
Could fixation explain weak or uneven NDRG3 staining?
Target-specific fixation sensitivity is unknown, and the selected paraffin-section caption does not state its fixative (datasheet A10017). Record the fixative and processing history for each specimen, then compare matched sections using the same citrate pH 6, 20-minute retrieval and antibody incubation (datasheet A10017; general IHC practice). For a controlled fixation comparison, document each condition explicitly, including any 10% neutral buffered formalin condition chosen for the experiment (general IHC practice). Judge differences against matched morphology and no-primary controls before assigning a weak result to fixation (general IHC practice).
Where should convincing NDRG3 staining appear?
Expect predominantly cytoplasmic tissue staining, with cytosol reported as the main subcellular location and vesicles as an additional location (HPA tissue IHC: cytoplasmic expression in most tissues; HPA subcellular: cytosol and vesicles). The record reports no transmembrane segment, but provides no UniProt subcellular annotation (UniProt Q9UGV2 topology and subcellular record). Compare the cellular pattern with documented high staining in cerebellar granular-layer cells and cerebral cortex neuronal cells (HPA: High in both cell populations). If nuclear or sharply membrane-restricted staining dominates, inspect morphology and controls before treating that pattern as NDRG3 localisation (HPA subcellular: cytosol and vesicles; general IHC practice).
Can isoforms or phosphorylation change what this antibody detects?
NDRG3 has 3 listed isoforms, while the supplied antibody caption does not identify its bound epitope (UniProt Q9UGV2 isoforms; datasheet A10017). The record lists modified residues including Thr322, Thr329, Ser331, and Thr332 (UniProt Q9UGV2 modified residues). Without an epitope map, neither isoform coverage nor sensitivity to these modifications can be assigned to the catalog antibody (UniProt Q9UGV2 isoforms and modified residues; datasheet A10017). For a disputed tissue pattern, obtain epitope information and compare appropriately characterised isoform or perturbation controls under the same retrieval and detection conditions (general IHC practice).
How should I assess NDRG3 in multiplex immunofluorescence?
Treat IF as a separate assay: the supplied A10017 evidence describes chromogenic IHC in paraffin-embedded rat brain, with no IF validation stated (datasheet A10017). Multiplex with a marker for the expected cell population, such as neuronal cells in cerebral cortex, and check whether NDRG3 signal falls within those cells (HPA: High in cerebral cortex neuronal cells; general IF practice). Select spectrally separated fluorophores after measuring tissue autofluorescence, and include single-stain and no-primary controls (general IF practice). Because cytosol is the approved main location and NDRG3 has no transmembrane segment, optimise permeabilisation for intracellular epitope access while preserving morphology (HPA subcellular: cytosol; UniProt Q9UGV2 topology; general IF practice).
How can I separate NDRG3 signal from chromogenic background?
The documented workflow used 10% goat serum blocking, a biotinylated secondary, streptavidin-biotin complex, and DAB (datasheet A10017). Run a no-primary section and assess endogenous biotin and peroxidase contributions before interpreting diffuse brown staining; a peroxidase block is a general chromogenic IHC step (general IHC practice). Keep the documented 1 μg/ml primary concentration and overnight 4°C incubation fixed while changing one blocking or detection variable at a time (datasheet A10017; general IHC practice). Compare cellular staining with expected cytoplasmic signal and inspect tissue edges or damaged regions separately (HPA tissue IHC: cytoplasmic expression; general IHC practice).
How should I score NDRG3 staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, because tissue staining is reported as cytoplasmic and varies by cell type (HPA tissue IHC: cytoplasmic expression and listed cell populations). For chromogenic sections, report the percentage of positive target cells and an H-score from 0–300 using intensity categories of 0–3 (general IHC practice). Normalise counts to the number of evaluable target cells, or use positive-cell density per mm² of viable tissue when area is the comparison unit (general IHC practice). Apply one staining batch, exposure and threshold policy to comparable sections, and exclude artefactual edges and necrotic areas consistently (general IHC practice).
What distinguishes a true NDRG3-positive cell from an artefact?
A credible result shows intracellular cytoplasmic signal in the scored cells, consistent with the tissue profile and the approved cytosolic location (HPA tissue IHC: cytoplasmic expression; HPA subcellular: cytosol). Cerebral cortex neuronal cells and cerebellar granular-layer cells are reported High, whereas adipocytes are reported Not detected, providing context for control selection (HPA: cerebral cortex, cerebellum, adipose tissue). Treat staining confined to nuclei, section edges, necrotic areas, or tissue-wide enzyme deposits as suspect until controls resolve it (HPA subcellular: cytosol; general IHC practice). Review a no-primary section and cellular morphology alongside the test section before calling an unexpected compartment or cell population positive (general IHC practice).
Boster reagents
Best NDRG3 / Protein NDRG3 IHC Antibodies
The catalog provides NDRG3 paraffin-section IHC images from rat and mouse brain and human mammary and intestinal cancers (A10017 image captions). It provides no IF images (catalog).
Real IHC data
Anti-NDRG3 Antibody ®
Cat # A10017
A10017 lists IHC for human, mouse and rat, with paraffin-section images from rat and mouse brain and human mammary and intestinal cancers (catalog applications and reactivity; A10017 image captions). M10017 lists IHC for human samples, but has no IHC image in the payload (catalog applications and reactivity; catalog image data).
Which to pick: Choose A10017 for paraffin-section tissue IHC and cross-species work because its own captions show staining in human, mouse and rat sections (A10017 image captions); the fixative is unreported (A10017 image captions). M10017 is a rabbit monoclonal listed for human IHC, with no IHC image supplied (catalog host, clone, applications and reactivity; catalog image data). Neither SKU lists IF/ICC or supplies an IF image, so this payload does not support an IF/ICC recommendation (catalog applications; catalog image data).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UGV2 (NDRG3_HUMAN, Protein NDRG3).
- Human Protein Atlas. NDRG3 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. NDRG3 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to vesicles..
- Human Protein Atlas. NDRG3 antibody validation summary (2 antibodies).
- Elevated N-Myc downstream-regulated gene 3 expression indicates poor survival in epithelial ovarian cancer. Medicine 2025 — PMC12091667.
- Relationship between serum NDRG3 and papillary thyroid carcinoma. Frontiers in endocrinology 2022 — PMC9811643.
- NDRG3 overexpression is associated with a poor prognosis in patients with hepatocellular carcinoma. Bioscience reports 2018 — PMC6435526.
- High NDRG3 expression facilitates HCC metastasis by promoting nuclear translocation of β-catenin. BMB reports 2019 — PMC6675243.
- PubMed PMID:11352569 — UniProt-cited evidence.
- PubMed PMID:11936845 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NDRG3 (Protein NDRG3). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A10017). Validated IHC antibody: A10017 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Cells in granular layer); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded rat brain tissues; fixative not specified (datasheet A10017); 2. Fixation: Image fixative and duration unreported (datasheet A10017); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A10017); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A10017); 8. Primary antibody: Rabbit anti-NDRG3, 0.5-1μg/ml (datasheet A10017); 9. Primary incubation: Overnight at 4 °C (datasheet A10017). Watch for: Fixation: Keep fixation consistent (standard IHC practice; not target-specific); target-specific effects are unknown.; Caveat: Staining and RNA show medium consistency; verify specificity (HPA tissue IHC); Isoform / epitope: 3 isoforms; check epitope coverage across variants (UniProt); Regulation: Brain-enhanced expression (UniProt; HPA RNA). Evidence: UniProt Q9UGV2, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to vesicles., Datasheet A10017, PMC12091667, PMC9811643. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NDRG3/immunohistochemistry-ihc-guide.